Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI

BACKGROUND AND OBJECTIVE: An adjusted indirect comparison was conducted to assess efficacy outcomes, particularly overall survival (OS), of osimertinib versus platinum-based doublet chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) T790M mutation-positive non-small-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Mann, Helen, Andersohn, Frank, Bodnar, Carolyn, Mitsudomi, Tetsuya, Mok, Tony S. K., Yang, James Chih-Hsin, Hoyle, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856890/
https://www.ncbi.nlm.nih.gov/pubmed/29247383
http://dx.doi.org/10.1007/s40261-017-0611-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856890/
https://www.ncbi.nlm.nih.gov/pubmed/29247383
http://dx.doi.org/10.1007/s40261-017-0611-3

Ejemplares similares